Abstract
Much of the information concerning pediatric rheumatologic diseases reported during the past year dealt with therapeutic and toxic effects of medications. Ibuprofen, the nonsteroidal anti-inflammatory drug most recently approved for use in children in the United States, was shown to be safe and effective in juvenile rheumatoid arthritis. Pilot studies of intravenous gammaglobulin in systemic juvenile rheumatoid arthritis, sulfasalazine in pauciarticular juvenile rheumatoid arthritis, and methotrexate in all juvenile arthritides also yielded promising results. On the other hand, little-recognized toxicities of nonsteroidal anti-inflammatory drugs, including nephrotic syndrome and a photodermatitis, were also highlighted. New demographic data were published concerning the resurgence of acute rheumatic fever, as well as the continuing severe morbidity suffered by children with systemic lupus erythematosus. Description of the first transgenic animal model of a human inflammatory disease, however, holds out the possibility of an entirely new approach to the rheumatic diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
